Question: Are Monster Beverage and Gilead Sciences both American companies?
Context: Blue Sky Beverage Company is an all natural beverage company that produces a large selection of natural soft drinks and energy drinks.  It is a wholly owned subsidiary of the Monster Beverage Corporation.  The company was established in Santa Fe, New Mexico, in 1980 where it remained until it was purchased by Monster (then Hansen Beverage) in 2000.  Coca-Cola North America took ownership of Blue Sky Sodas, Hansen’s Juice Products, Hansen’s Natural Sodas, Hubert’s Lemonade, Peace Tea and other non-energy drink brands as part of Coke’s partnership with Monster Beverage Corp on Jun 12, 2015. Monster Beverage Corporation is an American beverage company that manufactures energy drinks, natural soft drinks, and fruit drinks including Monster Energy, Hansen's Natural Soda, Hansen's Energy, Hansen's Junior Juice, Hubert's Lemonade, Peace Tea, and Blue Sky. Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.  For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Tenofovir alafenamide (INN/USAN; trade name Vemlidy) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir.  It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF).  Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent.  Gilead was awarded FDA approval in November 2016 for the drug Vemlidy. Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist.  Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension. Bictegravir (INN; formerly known as GS-9883) is an investigational new drug of the integrase inhibitor class that was discovered by scientists at Gilead Sciences; "in vitro" and clinical results were presented by Gilead in the summer of 2016.  As of June 2016 Bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection. John F. Milligan, Ph.D. is the CEO of Gilead Sciences, a biotechnology company based in the United States since March 2016.  He was previously appointed President of the company and has maintained that role since May 2008.  He has held various other positions during his tenure with Gilead which includes COO and CFO and originally joined the biotechnology company back in 1990 as a research scientist.  He was the 32nd employee hired by the company.  Milligan inherited his current role as CEO when former CEO John C. Martin was appointed to Executive Chairman. Douglas A. Melton is the Xander University Professor at Harvard University, and an investigator at the Howard Hughes Medical Institute.  Additionally, Melton serves as the co-director of the Harvard Stem Cell Institute and was the first co-chair (with David Scadden) of the Harvard University Department of Stem Cell and Regenerative Biology.  Melton is a founder of several biotech companies including Gilead Sciences, Ontogeny (now Curis), iPierian (now True North Therapeutics), and Semma Therapeutics.  Melton holds membership in the National Academy of the Sciences, the American Academy of Arts and Sciences, and is a founding member of the International Society for Stem Cell Research.  With his wife Gail O'Keefe, Melton serves as Co-Master of Eliot House, an undergraduate residence at Harvard College. John C. Martin (born 1951) is the executive chairman (2016-) and former CEO (1996-2016) of the American biotechnology company Gilead Sciences.  He joined Gilead Sciences in 1990 as Vice President for Research and Development.  In addition to helping developing other drugs such as Atripla (for HIV/AIDS), Martin led the team that developed Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C.  He is the recipient of a number of awards, including the Biotechnology Heritage Award (2017). Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.  After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.  The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Answer: yes